Meet-Test-Treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy.
Conjoint analysis
HCV
Healthcare services
Meet–Test–Treat
Point of care
Preferences
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
04 Jan 2022
04 Jan 2022
Historique:
received:
26
04
2021
accepted:
09
12
2021
entrez:
5
1
2022
pubmed:
6
1
2022
medline:
7
1
2022
Statut:
epublish
Résumé
It has been estimated that the incidence of chronic hepatitis C virus (HCV) will not decline over the next 10 years despite the improved efficacy of antiviral therapy because most patients remain undiagnosed and/or untreated. This study aimed to investigate the opinion of relevant target populations on the practicability, effectiveness and best modalities of the test-and-treat approach in the fight against HCV in Italy. A survey was delivered to patients with HCV from the general population, patients from drug addiction services, hospital physicians and healthcare providers for drug addiction services. For both hospital clinicians and SerD HCPs, tolerability is shown as the most important feature of a suitable treatment. Time to treatment (the time from first contact to initiation of treatment) is deemed important to the success of the strategy by all actors. While a tolerable treatment was the main characteristic in a preferred care pathway for general patients, subjects from drug addiction services indicated that a complete Meet-Test-Treat pathway is delivered within the habitual care center as a main preference. This is also important for SerD HCPs who are a strong reference for their patients; hospital clinicians were less aware of the importance of the patient-HCP relationship in this process. The health system is bound to implement suitable pathways to facilitate HCV eradication. A Meet-Test-Treat program within the drug addiction services may provide good compliance from subjects mainly concerned with virus transmission.
Sections du résumé
BACKGROUND
BACKGROUND
It has been estimated that the incidence of chronic hepatitis C virus (HCV) will not decline over the next 10 years despite the improved efficacy of antiviral therapy because most patients remain undiagnosed and/or untreated. This study aimed to investigate the opinion of relevant target populations on the practicability, effectiveness and best modalities of the test-and-treat approach in the fight against HCV in Italy.
METHODS
METHODS
A survey was delivered to patients with HCV from the general population, patients from drug addiction services, hospital physicians and healthcare providers for drug addiction services.
RESULTS
RESULTS
For both hospital clinicians and SerD HCPs, tolerability is shown as the most important feature of a suitable treatment. Time to treatment (the time from first contact to initiation of treatment) is deemed important to the success of the strategy by all actors. While a tolerable treatment was the main characteristic in a preferred care pathway for general patients, subjects from drug addiction services indicated that a complete Meet-Test-Treat pathway is delivered within the habitual care center as a main preference. This is also important for SerD HCPs who are a strong reference for their patients; hospital clinicians were less aware of the importance of the patient-HCP relationship in this process.
CONCLUSION
CONCLUSIONS
The health system is bound to implement suitable pathways to facilitate HCV eradication. A Meet-Test-Treat program within the drug addiction services may provide good compliance from subjects mainly concerned with virus transmission.
Identifiants
pubmed: 34983405
doi: 10.1186/s12879-021-06983-y
pii: 10.1186/s12879-021-06983-y
pmc: PMC8725306
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3Informations de copyright
© 2021. The Author(s).
Références
Int J Drug Policy. 2015 Oct;26(10):893-8
pubmed: 26254497
Int J Drug Policy. 2017 Sep;47:77-85
pubmed: 28578863
Int J Drug Policy. 2017 Sep;47:107-116
pubmed: 28797497
Rand Health Q. 2017 Jan 1;6(4):6
pubmed: 28983429
Eur J Gastroenterol Hepatol. 2015 Sep;27(9):1063-8
pubmed: 26049711
J Hepatol. 2018 Oct;69(4):762-764
pubmed: 30049544
Hepatology. 2014 Feb;59(2):366-9
pubmed: 23873507
J Am Pharm Assoc (2003). 2019 Sep - Oct;59(5):710-716
pubmed: 31227418
Adv Ther. 2019 Sep;36(9):2475-2486
pubmed: 31240629
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
Vaccines (Basel). 2020 Sep 14;8(3):
pubmed: 32937824
Lancet. 2011 Aug 13;378(9791):571-83
pubmed: 21802134
Addiction. 2021 Nov;116(11):3115-3126
pubmed: 33788326
Value Health. 2011 Jun;14(4):403-13
pubmed: 21669364
Gut. 2020 Oct 27;:
pubmed: 33109688
J Int AIDS Soc. 2017 Jul 28;20(1):22146
pubmed: 28782335
PLoS One. 2019 Jan 10;14(1):e0210179
pubmed: 30629662
Liver Int. 2018 Dec;38(12):2190-2198
pubmed: 29900654
Eur Rev Med Pharmacol Sci. 2016 Dec;20(1 Suppl):7-10
pubmed: 28083865
Scand J Infect Dis. 2009;41(9):689-99
pubmed: 19579149
Drug Alcohol Rev. 2019 Sep;38(6):644-655
pubmed: 31441565
Lancet. 2009 Jan 3;373(9657):48-57
pubmed: 19038438
Patient Prefer Adherence. 2020 Mar 19;14:613-624
pubmed: 32256052
Lancet Glob Health. 2020 Feb;8(2):e171-e172
pubmed: 31981548
Int J Drug Policy. 2019 Mar;65:1-7
pubmed: 30576938